Key result
A patient with stent thrombosis exhibited clopidogrel resistance due to a failure to metabolize clopidogrel into its active metabolite.
Case Report (n=1)
This case highlights the clinical risk of stent thrombosis in patients with clopidogrel resistance due to impaired drug metabolism.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to test clopidogrel metabolism after stent thrombosis; hypothesis-generating and should not yet change practice.
Clopidogrel has become the most widely used antiplatelet drug second to aspirin. Clopidogrel itself is a prodrug that is absorbed in the intestine and partially converted into 2-oxo-clopidogrel by a cytochrome P450 monooxygenase-dependent metabolism. The intermediate metabolite 2-oxoclopidogrel is further hydrolyzed to the active thiol metabolite of clopidogrel that irreversibly binds to the platelet Gi-coupled adenosine diphosphate (ADP) P2Y12 receptor. Recent studies have reported a considerable variability in clopidogrel-response
No takes yet. Share an insight, caveat, or question.
Taubert et al. (2005) conducted a case report in Stent thrombosis and clopidogrel resistance (n=1). Clopidogrel was evaluated. A patient with stent thrombosis exhibited clopidogrel resistance due to a failure to metabolize clopidogrel into its active metabolite.
Synapse has enriched 10 related papers. Consider them for comparative context: